Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo
Open Access
- 4 May 2007
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 56 (12) , 1875-1883
- https://doi.org/10.1007/s00262-007-0330-3
Abstract
Background We have treated three patients with carboxy-anhydrase-IX (CAIX) positive metastatic renal cell cancer (RCC) by adoptive transfer of autologous T-cells that had been gene-transduced to express a single-chain antibody-G250 chimeric receptor [scFv(G250)], and encountered liver toxicity necessitating adaptation of the treatment protocol. Here, we investigate whether or not the in vivo activity of the infused scFv(G250)+ T cells is reflected by changes of selected immune parameters measured in peripheral blood. Methods ScFv(G250)-chimeric receptor-mediated functions of peripheral blood mononuclear cells (PBMC) obtained from three patients during and after treatment were compared to the same functions of scFv(G250)+ T lymphocytes prior to infusion, and were correlated with plasma cytokine levels. Results Prior to infusion, scFv(G250)+ T lymphocytes showed in vitro high levels of scFv(G250)-chimeric receptor-mediated functions such as killing of CAIX+ RCC cell lines and cytokine production upon exposure to these cells. High levels of IFN-γ were produced, whilst production of TNF-α, interleukin-4 (IL-4), IL-5 and IL-10 was variable and to lower levels, and that of IL-2 virtually absent. PBMC taken from patients during therapy showed lower levels of in vitro scFv(G250)-receptor-mediated functions as compared to pre-infusion, whilst IFN-γ was the only detectable cytokine upon in vitro PBMC exposure to CAIX. During treatment, plasma levels of IFN-γ increased only in the patient with the most prominent liver toxicity. IL-5 plasma levels increased transiently during treatment in all patients, which may have been triggered by the co-administration of IL-2. Conclusion ScFv(G250)-receptor-mediated functions of the scFv(G250)+ T lymphocytes are, by and large, preserved in vivo upon administration, and may be reflected by fluctuations in plasma IFN-γ levels.Keywords
This publication has 25 references indexed in Scilit:
- Treatment of Metastatic Renal Cell Carcinoma With Autologous T-Lymphocytes Genetically Retargeted Against Carbonic Anhydrase IX: First Clinical ExperienceJournal of Clinical Oncology, 2006
- Adoptive immunotherapy for cancer: building on successNature Reviews Immunology, 2006
- Parallel Detection of Transduced T Lymphocytes After Immunogene Therapy of Renal Cell Cancer by Flow Cytometry and Real-Time Polymerase Chain Reaction: Implications for Loss of Transgene ExpressionHuman Gene Therapy, 2005
- Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: implications for clinical immunogene therapy of cancerCancer Gene Therapy, 2005
- Adoptive-cell-transfer therapy for the treatment of patients with cancerNature Reviews Cancer, 2003
- Cytokine gene polymorphisms in multifactorial diseases: gateways to novel targets for immunotherapy?Trends in Pharmacological Sciences, 2003
- Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancerCancer Gene Therapy, 2002
- Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCRGene Therapy, 2000
- Internal image anti-idiotype antibodies related to renal-cell carcinoma-associated antigen G250International Journal of Cancer, 1994
- Monoclonal antibody G 250 recognizes a determinant present in renal‐cell carcinoma and absent from normal kidneyInternational Journal of Cancer, 1986